A practical reference on half-life: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-08 and is reviewed periodically as new material appears.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Mesorchium Mesovarium Blood vessels: The superior mesenteric artery and the inferior mesenteric artery (the two main mesenteric arteries), and the superior mesenteric vein and the inferior mesenteric vein (the two main mesenteric veins), plus their branches and the capillaries
== History == The discovery of coordination polymers, or as later termed metal-organic frameworks, was a logical continuation of research on post-zeolite materials. In 1989 Richard Robson reported the first organic copper-based coordination network by complexation of anions with tetrahedral bridging ligands. Similar copper(I) coordination polymers have been synthesized in 1992 by Susumu Kitagawa, which contained pores with loosely bound acetone molecules, but the structure would collapse upon their removal. Further efforts were devoted to develop extended 3D porous networks that would be stable upon removal of guest molecule and would exhibit permanent porosity. In 1995, Omar M. Yaghi demonstrated interpenetrated 2-D structure with carboxylate-based linkers that remained stable upon guest removal and could re-adsorb specific aromatic molecules. Permanent porosity in 3-D coordination polymer was first demonstrated in 1997 by Susumu Kitagawa. A year later, Yaghi proposed a new synthetical concept that employs secondary building units (SBUs) — metal-carboxylate clusters that serve as rigid building blocks for constructing frameworks with permanent porosity. In 1999, Yaghi and colleagues used SBU approach to synthesize MOF-5 that consists of zinc oxide clusters and terephthalate linkers. MOF-5 exhibits strong bonds between metal centers and coordinating organic molecules and hence exhibits high thermal stability while maintaining high porosity..
Operating in Cuba was technically a violation of their jurisdiction, and they are usually not considered the "first" Cuban non-military Lodges, because they were not chartered to operate here. They spoke French at meetings, wrote their materials in French, and continued to use their French Lodge names, instead of changing them to the local Spanish.
=== Footwear === Diabetic shoes, insoles and socks are personalised products that relieve pressure on the foot in order to prevent ulcers. The evidence for special footwear to treat foot ulcers is poor but their effectiveness for prevention is well-established. Design features of footwear that are effective in reducing pressure are arch supports, cushioned cut-outs around points at risk of damage, and cushioning at the ball of the foot. Technology for measuring the pressure within the shoes is recommended during the design of diabetic footwear. People with loss of feeling in their feet should not walk around barefoot, but use proper footwear at all times.
Sources: en.wikipedia.org
As pointed out by Peter Ward and Donald Brownlee in their book The Life and Death of Planet Earth, the process of ocean loss has only been documented twice: first during the Apollo 16 Moon mission, when the mission's astronauts observed Earth using a unique Carruthers camera, and again during the 1990s through studies based on observations made by astronauts aboard the Space Shuttle. Saturn's moon Titan has a very weak cold trap that is only able to retain some of its atmospheric methane. Thus, it has been suggested that Titan is the closest analog to what Earth's atmosphere will look like as Earth's cold trap fails, with methane instead of water and hydrocarbon products of photochemistry instead of oxygen and ozone. Cold traps are thought to function for oxygen on Ganymede.
There were a few similar spark discharge experiments contemporaneous with Miller–Urey. An article in The New York Times (March 8, 1953) titled "Looking Back Two Billion Years" describes the work of Wollman M. MacNevin at Ohio State University, before the Miller Science paper was published in May 1953. MacNevin was passing 100,000V sparks through methane and water vapor and produced "resinous solids" that were "too complex for analysis." Furthermore, K. A. Wilde submitted a manuscript to Science on December 15, 1952, before Miller submitted his paper to the same journal in February 1953. Wilde's work, published on July 10, 1953, used voltages up to only 600V on a binary mixture of carbon dioxide (CO2) and water in a flow system and did not note any significant reduction products. According to some, the reports of these experiments explain why Urey was rushing Miller's manuscript through Science and threatening to submit to the Journal of the American Chemical Society. By introducing an experimental framework to test prebiotic chemistry, the Miller–Urey experiment paved the way for future origin of life research. In 1961, Joan Oró produced milligrams of the nucleobase adenine from a concentrated solution of HCN and NH3 in water. Oró found that several amino acids were also formed from HCN and ammonia under those conditions. Experiments conducted later showed that the other RNA and DNA nucleobases could be obtained through simulated prebiotic chemistry with a reducing atmosphere.
== Common names == Eurycoma longifolia is also known by the common names penawar pahit, penawar bias, bedara merah, bedara putih, lempedu pahit, payong ali, tongkat baginda, muntah bumi, petala bumi, bidara laut (all Malay-Indonesian); babi kurus (Javanese); cây bá bệnh (Vietnamese); tho nan (Laotian); lan-don, hae phan chan, phiak, plaa lai phuenk, tung saw (all Thai); "long jack" (US); langir siam (Bahrain). Many of the common names refer to the plant's medicinal use and extreme bitterness. Penawar pahit translates simply as "bitter charm" or "bitter medicine". Older literature, such as a 1953 article in the Journal of Ecology, may cite only penawar pahit as the plant's common Malay name. E. longifolia is known by common names "tongkat ali" and "pasak bumi" in the South East Asian region, but these names are also used for similar species, Polyalthia bullata. The bark and root of E. longifolia is more white/yellow-ish compared to the darker-colored P. bullata, which has led to the former being known as "tongkat ali/pasak bumi putih" or "tongkat ali/pasak bumi kuning", and the latter as "tongkat ali/pasak bumi hitam". ("Putih" means "white", "kuning" means "yellow", and "hitam" means "black" in Malay/Indonesian.) Indonesia also has a red-coloured variety known as "tongkat ali/pasak bumi merah" ("merah" meaning "red"), which is being studied by researchers and has not had its species classified. Eurycoma longifolia is also known by the species name Eurycoma longifolia Jack, as this was the name used by botanist William Jack in his taxonomical description published in 1822.
=== Herbicide-resistant crops === Commercial varieties of important agricultural crops (including soy, maize/corn, sorghum, canola, alfalfa and cotton) have been developed that incorporate a recombinant gene that results in resistance to the herbicide glyphosate (trade name Roundup), and simplifies weed control by glyphosate application. These crops are in common commercial use in several countries.
Faculty member Isabelle Rapin has been described as a "founding mother of autism" and popularized the term "autism spectrum disorder". In 2019, researchers at Einstein mapped the entire nervous system of Caenorhabditis elegans, a classic model organism. Other work includes the discovery of the Tc1/mariner transposon superfamily and the invention of single molecule mRNA fluorescent in situ hybridization.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.